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Paragangliomas are rare neuroendocrine tumors that arise in the sympathetic or parasympathetic nervous system. Sympathetic
paragangliomas are mainly found in the adrenal medulla (designated pheochromocytomas) but may also have a thoracic,
abdominal, or pelvic localization. Parasympathetic paragangliomas are generally located at the head or neck. Knowledge
concerning the familial forms of paragangliomas has greatly improved in recent years. Additionally to the genes involved in
the classical syndromic forms: VHL gene (von Hippel-Lindau), RET gene (Multiple Endocrine Neoplasia type 2), and NF1 gene
(Neurofibromatosis type 1), 10 novel genes have so far been implicated in the occurrence of paragangliomas/pheochromocytomas:
SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX, EGLN1, HIF2A, and KIF1B. It is currently accepted that about 35% of the
paragangliomas cases are due to germlinemutations in one of these genes. Furthermore, somaticmutations ofRET,VHL,NF1,MAX,
HIF2A, andH-RAS can also be detected.The identification of the mutation responsible for the paraganglioma/pheochromocytoma
phenotype in a patient may be crucial in determining the treatment and allowing specific follow-up guidelines, ultimately leading
to a better prognosis. Herein, we summarize the most relevant aspects regarding the genetics and clinical aspects of the syndromic
and nonsyndromic forms of pheochromocytoma/paraganglioma aiming to provide an algorithm for genetic testing.
1. Introduction
Paragangliomas are neuroendocrine tumors that can origi-
nate in either the parasympathetic or sympathetic nervous
system. Most parasympathetic paragangliomas are chro-
maffin-negative (meaning that they do not stain brown when
exposed to potassium dichromate) and do not secrete cat-
echolamines. Sympathetic paragangliomas (including those
derived from the adrenal medulla) are chromaffin-positive
tumors that generally secrete catecholamines [1].
The designation of pheochromocytoma appears in the
literature associated with different meanings. The World
Health Organization (WHO) Tumor Classification defines
pheochromocytoma as a paraganglioma derived from the
adrenal medulla [2], whilst some authors use the term pheo-
chromocytoma to refer to catecholamine-producing para-
gangliomas independently of being adrenal or extra-adrenal.
In the present revision, we will use the WHO classification.
Sympathetic paraganglia are mainly found in the adrenal
medulla but also in the axial regions of the trunk along
the prevertebral and paravertebral sympathetic chains and
in the connective tissue within/near pelvic organs. In con-
trast, parasympathetic paraganglia are almost exclusively
confined to the head and neck in the vicinity of major
arteries and nerves [3]. Paragangliomas can be categorized
into functioning/nonfunctioning according to their ability
to secrete catecholamines. Sympathetic tumors (including
pheochromocytomas) tend to hypersecrete catecholamines
(up to 90%), whereas only about 5% of parasympathetic
paragangliomas secrete catecholamines [4, 5]. Among the
functioning paragangliomas, the pheochromocytomas are
the most frequent (80–85% of the cases) followed by the
extra-adrenal abdominal paragangliomas [4–6].
The clinical presentation of these patients is highly
variable, with most symptoms being nonspecific and mim-
icking other clinical conditions. Headaches, hypertension,
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tachycardia, diaphoresis, pallor, anxiety, and panic attacks
are the most frequent signs and symptoms at presentation
[6]. The classic triad of palpitations, headaches, and profuse
sweating altogether can provide a specificity of more than
90% [7]. Paroxysmal hypertension is frequent, either in
patients with sustained hypertension or normal blood pres-
sure. In fact, these patients typically present paroxysmal signs
and symptoms (lasting less than an hour) that result from
episodic release of catecholamines usually due to a triggering
factor (surgery, stress, exercise, certain foods, medications,
alcohol, etc.) [6]. Signs and symptoms in patients harboring
parasympathetic paragangliomas are related to their mass
effect causing compression of adjacent tissues and nerves,
such as cranial nerves IX–XII [8, 9].
Paragangliomas are rare tumors occurringwith an overall
estimated incidence of 1/300 000, with an average age at
diagnosis of around 40 years and no gender differences
[2, 4, 10, 11]. However, the incidence of these tumors is
much higher at autopsy (≈ 0.05%), probably due to the
often-asymptomatic clinical course of these tumors that, on
the other hand, may result in premature mortality [12–14].
In hypertensive patients’ series, the prevalence of paragan-
gliomas/pheochromocytomas ranges from 0.1 to 0.6% [15–
17].
Although most tumors are benign, about 10% of pheo-
chromocytomas and 15% to 35% of extra-adrenal paragan-
gliomas are malignant [18]. Prior to the appearance of distant
metastases, commonly found in lungs, bone, or liver, there
are no reliable histological, genetic, or imaging markers to
predict malignancy of these tumors [18]. The histological
PASS (Pheochromocytoma of the Adrenal gland Scaled
Score) system was developed to predict the risk of malignant
pheochromocytomas; however, the high interobserver and
intraobserver variations make this score of limited clinical
use [19–21]. Some studies have also pointed out that the size
and location of the tumor, the downregulation of metastasis
suppressor genes, early onset postoperative hypertension,
high levels of plasma/urine metanephrines, immunochem-
ical expression of the angiogenesis-related genes, and high
levels of serum chromogranin A at the time of diagnosis,
amongst many others, increase the likelihood of malignant
pheochromocytoma [18, 22–25]. Of particular importance
are the germline mutations in the SHDB gene (discussed in
detail later), which have been associated with up to 72% of
malignant tumors [26].
Paragangliomas can be classified into either sporadic
or familial. In the last years, our knowledge concerning
the familial forms of paragangliomas has greatly improved.
Additionally to the genes involved in the classical syndromic
forms: VHL gene in von Hippel-Lindau disease, RET gene
in Multiple Endocrine Neoplasia type 2 (MEN 2), and
NF1 gene Neurofibromatosis type 1, 10 novel genes have so
far shown to be implicated in the occurrence of paragan-
gliomas/pheochromocytomas [27–29]. Amongst these, the
most relevant are those of the mitochondrial succinate dehy-
drogenase (SDH) complex subunits genes (SDHA, SDHB,
SDHC, and SDHD) and one complex cofactor, SDHAF2,
mainly involved in head and neck and abdominal paragan-
gliomas and initially discovered by Baysal et al. [30–34].More
recently, the TMEM127, MAX, HIF2A, EGLN1, KIF1B, and
H-RAS complete the list of susceptibility genes implicated
in the development of paragangliomas/pheochromocytomas
[35–40]. So far, H-RAS mutations have been identified only
at a somatic level.
Pheochromocytoma (here meaning catecholamine-
secreting paraganglioma) was known as the 10% tumor,
meaning that 10% of cases were familial, 10% bilateral,
10% malignant, and 10% extra-adrenal [1]. The 10 percent
dogma concerning the hereditary forms of these tumors
was completely discarded by a study in 2002 by Neumann
et al. [41]. In this study, it was found that 24% of the patients
who presented with nonsyndromic pheochromocytoma
and without family history of the disease had mutations
in VHL, RET, SDHD, and SDHB genes. Younger age at
presentation (24.9 versus 43.9 years of age), multiple tumors
(32% versus 2%), and presence of extra-adrenal tumors (28%
versus 8%) were significantly associated with the presence
of a mutation [41]. In 2006, a study comprising a larger
number of patients with pheochromocytoma/paraganglioma
showed that 33% of the patients carried germline mutations
in one of the following genes: VHL, RET, NF1, SDHB, and
SDHD [42]. So, it is currently accepted that up to 35% of
paragangliomas/pheochromocytomas are associated with an
inherited mutation [43, 44].
In this review, we summarize the clinical and genetic
aspects of the syndromic and nonsyndromic forms of
pheochromocytoma/paraganglioma. The risk of developing
pheochromocytoma/paraganglioma will be addressed for
each gene. A clinically oriented strategy for genetic testing
will be discussed.
2. Genetics of Paragangliomas/
Pheochromocytomas
2.1. Syndromic Forms
2.1.1. von Hippel-Lindau. von Hippel-Lindau (VHL) disease
is an autosomal dominant syndrome characterized by a
variety of benign andmalignant tumors including retinal and
central nervous system hemangioblastomas, clear renal cell
carcinoma and renal cysts, pheochromocytomas, pancreatic
islet cell tumors and pancreatic cysts, epididymal cystadeno-
mas, and endolymphatic sac tumors [27].
This disease affects about 1 in 36 000 live births and is
divided into 2 clinical categories according to absence (type
1) or presence (type 2) of pheochromocytomas, respectively
[45, 46]. VHL type 2 is further divided in type 2A, iden-
tifying patients with low risk of developing clear renal cell
carcinoma, type 2B, for patients with high risk of developing
clear renal cell carcinoma, and type 2C, for patients that
only present pheochromocytomas without the other classical
lesions of VHL disease [27]. Pheochromocytomas occur in
10–20% of VHL patients, typically around 30 years, but
rare cases have been described below the age of 10. About
5% of pheochromocytomas in VHL disease are malignant
[27, 47, 48]. Due to the early onset of these tumors and
frequent absence of signs and symptoms, it has been proposed
that catecholamine screening should begin at the age of 2,
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especially in patients with a familial history of pheochromo-
cytomas [47]. VHL-associated pheochromocytomas secrete
mostly norepinephrine due to low or absent expression
of phenylethanolamine N-methyltransferase; thus, patients
present with increased plasma and urinary normetanephrine
[49]. The adrenal medulla is the most common paraganglia
affected in VHL type 2 patients but rare sympathetic and
parasympathetic paragangliomas have also been described
[27, 47, 50]. Pheochromocytomas are often bilateral and
generally have a good prognosis [51, 52].
vonHippel-Lindau protein (pVHL) is a tumor suppressor
protein that regulates the activity of hypoxia-inducible factor
alpha (HIF𝛼) and several other proteins involved in tumori-
genesis [53]. In normoxic conditions, pVHL binds to the 𝛼
subunits of HIF1 and 2, targeting it for ubiquitination and
proteasomal degradation. Conversely, in hypoxic conditions
or when VHL gene is mutated, HIF𝛼 is able to interact with
HIF𝛽, inducing the transcription of hypoxia-inducible genes,
leading to an increased expression of angiogenic growth
and mitogenic factors [53–55]. This disruption of pVHL-
mediated degradation of HIF will ultimately contribute to
tumor formation through multiple mechanisms [53].
VHL gene was mapped to the short arm chromosome 3
(3p25), it comprises 3 exons that encode for the 2 isoforms of
the pVHL protein [56]. More than 150 VHL germline muta-
tions have been associated to the VHL disease. These muta-
tions are missense, deletion, nonsense, or frameshift muta-
tions and are distributed throughout the coding sequence
[57, 58]. Although genetic testing studies have been able to
identify mutations in virtually every VHL-affected family,
diagnosis is still challenging in up to 20% of affected kindreds
in which a de novo mutation occurs [58, 59]. Genotype-
phenotype correlation studies have shown that VHL type
1 families frequently harbor VHL deletions or nonsense
mutations, whereas families at risk for developing pheochro-
mocytoma (type 2 families) almost invariably present with
VHL missense mutations [57, 58, 60]. Particularly, missense
mutations at codon 167 were associated with a high risk of
developing pheochromocytoma (53% and 82% at ages 30
and 50 years, resp.) [60]. VHL mutations associated with
the phenotype 2A or 2B have been shown to affect the
proteasomal degradation of HIF1, whereas type 2Cmutations
do not disrupt the ability of pVHL to downregulate HIF1,
suggesting that pheochromocytoma formation is not related
with HIF1 expression levels [61, 62]. It has been proposed
that VHL-associated pheochromocytoma tumorigenesis is
related with an abnormal extracellular matrix formation and
to upregulation of tyrosine hydroxylase, leading to increased
catecholamine synthesis [61, 63, 64].
2.1.2. Multiple Endocrine Neoplasia Type 2. Multiple endo-
crine neoplasia type 2 (MEN 2) is an autosomal domi-
nant cancer syndrome characterized by the association of
medullary thyroid carcinoma (MTC), pheochromocytoma,
and hyperparathyroidism [29]. Depending on the most
frequent manifestations, there are three subtypes MEN 2A,
MEN 2B, and Familial MTC (FMTC): in MEN 2A patients,
MTC is present in virtually all patients, unilateral or bilat-
eral pheochromocytoma in 50% of cases, and multigland
parathyroid tumors in 20–30% of cases; in MEN 2B patients,
the third component (hyperparathyroidism) is not present,
MTC has an earlier onset, and there are developmental
alterations such as multiple mucosal ganglioneuromas and a
“marfanoid” habitus; in FMTC patients, MTC is the single
manifestation [65–67]. MEN 2A is the most frequent subtype
representing over 75% ofMEN2 cases [66]. It is now accepted
that FMTC might be a variant of MEN 2A with a lower
clinical penetrance of pheochromocytoma [67, 68].
The genetic basis forMEN2 syndrome lieswithin the long
arm of chromosome 10 (10q11.2), where theRET (REarranged
during Transfection) protooncogene is located. It comprises
21 exons that encode for a tyrosine transmembrane recep-
tor with three domains: extracellular, transmembrane, and
intracellular. When a ligand of the glial-derived neurotropic
factor (GDNF) family binds to RET protein, it triggers RET
dimerization and autophosphorylation, inducing a signaling
phosphatidylinositol 3󸀠-kinase- (PI3K-) mediated cascade
that regulates cell proliferation and apoptosis. This requires
the presence coreceptors of the GDNF family receptor-𝛼1–4
(GFR-𝛼1–4) at the cell surface [69].
MEN 2 subtypes have been associated with specific RET
mutations. More than 98% of MEN 2A families present with
missense mutations in one of five codons: 609, 611, 618, 620
(exon 10), or 634 (exon 11). Codon 634 mutations represent
almost 90% of MEN 2A cases and a cysteine to arginine
substitution at this codon (p.Cys634Arg) is found in more
than 50% of cases [70–73]. All these mutations affect cysteine
residues in theRET extracellular domain and induce a ligand-
independent dimerization of RET, leading to a constitutive
activation of its intrinsic tyrosine kinase [74–76]. About 80%
of patients with FMTC present with a similar mutational
spectrum of MEN 2A, but mutations are relatively evenly
distributed among codons 618, 620, and 634 [70–73]. Inter-
estingly, the p.Cys634Arg mutation is almost never found
in FMTC families [67]. Generally, MEN 2B tumors are a
consequence of mutations in the substrate binding pocket
of the RET tyrosine kinase. A single missense mutation in
codon 918 (p.Met918Thr) is responsible for over 90% ofMEN
2B cases, whereas other rare mutations have been descri-
bed in exons 14 and 15 [69, 71–73]. The American Thyroid
Association (ATA) proposed the categorization of patients
into four risk levels (A to D) based on the mutation identified
and on the genotype-phenotype correlation. Clinical rec-
ommendations concerning prophylactic surgeries in asymp-
tomatic individuals depend on the attributed risk level [67].
Pheochromocytomas in MEN 2A and B syndromes are
generally benign tumors and bilateral in >50% of the patients
[29]. Extra-adrenal paragangliomas have been described
but are very rare [29, 77]. The biochemical phenotype of
these tumors is increased plasma and urinary levels of
metanephrine as a result of epinephrine hypersecretion,
possibly due to overexpression of phenylethanolamine N-
methyltransferase [49]. Large cohort series show that malig-
nancy affects less than 5% ofMEN2-associated pheochromo-
cytomas [78, 79].
Based on a large study enrolling 323 MEN 2A patients,
Quayle et al. reported an overall penetrance of pheochro-
mocytoma of 32%, with a median age at diagnosis of
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34 years; the earliest pheochromocytoma was observed at
15 years; bilateral pheochromocytomas were observed in
66% of patients; the following codon-specific expression of
pheochromocytoma was observed: codon 634 was expressed
in 50%, codon 618 was expressed in 22%, codon 620 was
expressed in 9%, and codon 609 was expressed in 4%. The
mean age at diagnosis did not differ amongst these codon-
grouped patients [80].
Childhood pheochromocytoma is rare in MEN 2, but
reports at 12 years of age have occurred for both the 918 and
634 RETmutations [79, 81].Therefore, the ATA recommends
that pheochromocytoma screening (by plasma or 24-hour
urine fractionated metanephrines) should begin by age 8
in carriers of RET mutations associated with MEN 2B and
mutated RET codons 634 and 630 and by the age 20 years in
carriers of other MEN 2A RET mutations. Patients with RET
mutations associated only with FMTC should be screened at
least periodically from the age of 20 years [67].
2.1.3. Neurofibromatosis Type 1. Neurofibromatosis type 1
(NF 1), or vonRecklinghausen’s disease, is an autosomal dom-
inant disorder clinically diagnosed by six or more cafe au lait
macules; two or more cutaneous/subcutaneous neurofibro-
mas or a single plexiform neurofibroma; axillary or inguinal
freckling; optic nerve glioma; two or more Lisch nodules (iris
hamartomas); dysplasia of long bones or pseudarthrosis; and
a first degree relative with NF1 [28, 82]. Patients with NF 1
are also at higher risk than general population of developing
various tumors such as peripheral nerve sheath tumors,
gastrointestinal stromal tumors, rhabdomyosarcoma, breast
cancer, and pheochromocytomas [83, 84]. Worldwide birth
incidence of NF 1 is 1 in 2 500–3 000 and prevalence is at least
1 in 4 000 [84].
NF 1 is caused by loss of functionmutations in the tumor-
suppressor NF1 gene [85]. This gene is located on chromo-
some 17q11.2 comprising 60 exons that encode for neurofi-
bromin, a negative regulator of RAS proteins. Neurofibromin
is a GTPase activating protein that promotes the conversion
of active RAS-GTP to its inactive form, RAS-GDP.Mutations
in NF1 gene result in constitutive activation of RAS activity
triggering a kinase cascade and the activation of mitogen-
activated protein kinases (MAPK), mammalian target of
rapamycin (mTOR), andPI3Kpathways, therefore regulating
the transcription of genes associated with cell proliferation,
cell death, differentiation, and migration [86]. Mutational
analysis inNF 1 patients remains a considerable challenge due
to the occurrence of different types of mutations (nonsense,
missense, or deletions) that span the entire length of the NF1
gene, the presence of 36 pseudogenes, and the fact that nearly
half of NF 1 cases present de novomutations [87, 88].
Pheochromocytomas are a rare feature in NF 1, affecting
approximately 0.1% to 6%of all patients [83, 89]. A prevalence
rate as high as 13% has been reported in autopsy series,
suggesting that the diagnosis of pheochromocytoma may
be missed in some NF 1 patients [89]. The mean age at
presentation of pheochromocytoma is 42 years. The majority
of patients have unilateral adrenal tumors, whereas 10% of
patients present with bilateral and 6% abdominal tumors.
Malignant pheochromocytomas were identified in 12% of
the NF 1 patients [42, 89]. Similarly to MEN 2-associated
pheochromocytomas, in NF 1 these tumors have been shown
to producemore epinephrine and less norepinephrine, result-
ing in increased levels of metanephrine [49]. Although
pheochromocytoma NF 1-associated is rare, due to the risk
of malignancy, it has been proposed that any patient with
hypertension/paroxysmal hypertension or with symptoms of
catecholamine excess, such as headache, sweating, palpita-
tions, or anxiety, should undergo measurement of 24-hour
urine or plasma metanephrines [28].
Unlike mutations in VHL or MEN 2 disorders, NF 1
mutations that offer an increased risk in pheochromocytoma
remain to be identified. A study carried out by Bausch et al.
in NF 1 patients with associated pheochromocytoma showed
that the cysteine-serine rich domain was affected in 35% of
the cases whereas the Ras GTPase activating protein domain
in only 13%, suggesting that the cysteine-serine rich could
play a role in the formation of NF1-associated pheochromo-
cytoma. Moreover, in accordance with the Knudson’s two-
hit theory that states that pheochromocytoma development
requires biallelic inactivation, loss of heterozygosity (LOH)
was shown in NF 1-related pheochromocytoma. No associ-
ation was found between NF1 mutational genotype and the
clinical features of pheochromocytoma [90].
2.2. Familial Paraganglioma Syndromes (SDHx and SDHAF2).
Familial paraganglioma syndromes (PGLs) are a group of
autosomal dominant disorders responsible for the devel-
opment of paragangliomas/pheochromocytomas caused by
mutations in the genes encoding for the succinate dehydro-
genase (SDH) mitochondrial complex. SDH or respiratory
complex II is an enzyme complex that catalyses the oxidation
of succinate to fumarate in the Krebs cycle and participates
in the electron transport chain [91]. SDH is composed of 4
subunits encoded by the corresponding genes: SDHA, SDHB,
SDHC, and SDHD. Complex subunits A (flavoprotein) and
B (iron-sulfur protein) constitute the catalytic core of the
enzyme, while subunits C and D anchor the complex to
the inner mitochondrial membrane. In general, inactivating
mutations in one of the SDHx genes leads to accumulation
of succinate and formation of reactive oxygen species, stabi-
lizingHIF𝛼 and activating hypoxia-dependent pathways [91].
Four PGL syndromes have been described: types 1, 2, 3, and 4,
caused by mutations in the SDHD, SDHAF2 (responsible for
the flavination of subunit A), SDHC, and SDHB, respectively
[30–33]. Immunohistochemistry can be used to triage genetic
testing of paraganglioma/pheochromocytoma. Particularly
for SDHB immunohistochemistry, a negative staining ismore
commonly found associated with SDHBmutation, whereas a
weak diffuse staining often occurs with SDHDmutation [92,
93]. Functioning SDHx paragangliomas sometimes release
dopamine and/or norepinephrine, originating raised plasma
levels of methoxytyramine, contributing to distinguish SDHx
patients from those with VHL, RET, or NF1 mutations [49,
94]. However, methoxytyramine should be regarded as a
useful biomarker of malignancy in the setting of paragan-
glioma/pheochromocytoma independent of the underlying
gene. Penetrance and clinical presentation of PGL syndromes
varies significantly with the underlying mutation [95].
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2.2.1. PGL 1 Syndrome. PGL 1 syndrome is caused by muta-
tions in SDHD gene, which are inherited in an autosomal
dominant fashion with a predominant paternal transmission,
suggesting a maternal imprinting of this gene [30, 34, 44,
96]. However, rare cases of maternal transmission have been
described and the precise mechanism responsible for this
parent-of-origin effect remains to be elucidated [97–99]. A
three-hit model has been hypothesized requiring a SDHD
mutation, loss or mutation of the wild-type SDHD allele,
and loss of a further imprinted (paternally silenced and
maternally active) tumor suppressor gene from chromosome
11 [99, 100]. PGL 1 patients generally present with multiple
benign parasympathetic head and neck paragangliomas,
but multiple sympathetic and adrenal tumors are also very
frequent. In fact, Neumann et al. have shown that among
34 patients with mutations in SDHD gene, 79% had head
and neck paraganglioma, 53% had pheochromocytoma, and
39% thoracic/abdominal paraganglioma, whereas 74% of the
patients presented with multiple tumors [96]. Mean age at
presentation is around 30 years [43, 96, 101, 102]. Ricketts
et al. estimated the risk of developing head and neck para-
gangliomas at 71% and the risk of pheochromocytoma at 29%,
at age 60 [102]. Malignancy has rarely been found in SDHD-
derived sympathetic or parasympathetic paragangliomas [43,
96, 101–105]. Several different mutations have been described
in exons 2–4 of SDHD, mainly nonsense, missense, and
frameshift, but its relation with the phenotypic expression of
the disease is still unclear [43, 96, 101, 102].
2.2.2. PGL 2 Syndrome. Familial PGL 2 syndrome is a very
rare condition characterized by multiple head and neck para-
gangliomas, of which only few cases have been reported [106,
107]. It happens as a consequence of mutations in SDHAF2
gene (also known as SDH5) that encodes for a succinate
dehydrogenase complex assembly factor 2 (SDHAF2), which
is responsible for the flavination of SDHA enabling SDH
complex activity [31]. To our knowledge, only two apparently
unrelated kindreds (of Dutch and Spain origin) have been
described as carriers of a missense mutation in this gene,
c.232G > A (p.Gly78Arg) [31, 106, 107]. Both kindreds show
a high penetrance for this mutation, which has a paternal
mode of transmission. Among the 16 mutations carriers of
the largest branch of the Dutch family, considered as at-risk
patients, 11 patients had head and neck tumors, out of which
10 had multiple tumors (91%).Themean age of diagnosis was
33 years [107].
The scarcity of SDHAF2 mutations was reinforced by
the failure to document mutations in this gene among 315
patients with paraganglioma and without mutations in the
SDHD, SDHC, or SDHB genes. Nonetheless, it is justified to
screen for SDHAF2mutations in young patients with isolated
head and neck paragangliomas or in individuals with familial
antecedents who are negative for other risk genes [106].
2.2.3. PGL 3 Syndrome. Mutations in the SDHC gene are
causative for familial PGL syndrome 3, which has an auto-
somal dominant mode of transmission without a parent-
of-origin effect [32]. This is a rare condition characterized
by benign parasympathetic head and neck tumors, but rare
cases of sympathetic paragangliomas and pheochromocy-
tomas have been described [44, 108–111]. In the studies by
Burnichon et al. [44] and Schiavi et al. [112], the mean age at
presentationwas 38 (17–70) and 46 years (13–73), respectively.
About 4% of paraganglioma patients carry mutations
in the SDHC gene [44, 112]. Different types of mutations
(missense, nonsense, splicing, deletions, and insertions)
encompassing the whole SDHC gene have been found [44,
105, 109, 112]. Malignancy associated with SDHC gene is
extremely rare with only two cases described so far, with
distinct causal mutations [113, 114].
2.2.4. PGL 4 Syndrome. Familial PGL 4 syndrome is chara-
cterized by abdominal and pelvic catecholamine-secre-
ting paragangliomas, which can also be present in adre-
nal medulla and head and neck [94, 102, 112, 115]. Symp-
toms are those classically associated with paraganglioma/
pheochromocytoma (headache, palpitations, and diaphore-
sis) but can also be due to a mass effect rather than cate-
cholamine secretion [94]. Mean age at diagnosis is around 32
years [94, 96, 102, 115]. Primary tumors are usually large and
associated with a high rate of malignancy ranging from 31 to
72% of patients [26, 94, 96, 115].
Germline mutations in SDHB gene, which encodes for
the iron sulfur subunit of the SDH complex (subunit B), are
responsible for PGL 4 familial syndrome [33]. Functional
assays have shown that these mutations lead to stabilization
of HIF1𝛼, causing overexpression of hypoxia-induced angio-
genic pathway genes, such as VEGF (vascular endothelial
growth factor) and EPAS1 (endothelial PAS domain protein
1), providing therefore support for tumor growth [116–118].
Loss of heterozygosity has been shown to occur as a conse-
quence of SDHB mutations [33, 116]. Of interest, mutations
in SDHB gene have also been associated with an increased
susceptibility to develop other neoplasms, namely, renal cell
carcinoma, gastrointestinal stromal tumors, papillary thyroid
cancer, and neuroblastoma [96, 102, 115, 119].
A wide spectrum of SDHB mutations have been found
associated with PGL 4, namely, missense, frameshift, splic-
ing, nonsense, and large deletions. However, several stud-
ies have failed to unveil genotype-phenotype correlations,
particularly in what concerns tumor location, age of pre-
sentation, and aggressiveness of the tumor [94, 120]. Since
mutations in SDHB gene are the most frequent cause of
metastatic paraganglioma tumors, it has consistently been
proposed that all patients presenting with malignant para-
ganglioma/pheochromocytoma should be tested for SDHB
gene mutations.
2.2.5. SDHA. The long-sought link between SDHA gene
and paraganglioma development was only unveiled in 2010,
when a patient with an extra-adrenal paraganglioma was
found to have an SDHA missense mutation [34]. Functional
studies show that SDHA, like other SDHx genes, operates
as tumor suppressor gene and activates the pseudohypoxic
pathway leading to tumorigenesis. Furthermore, in accor-
dance with Knudson’s two-hit hypothesis, it was shown that
the SDHA-mutated tumors have lost the wild type allele
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[34, 121]. The few SDHA-affected individuals described so
far have presented with distinct phenotypic characteristics:
pheochromocytoma, sympathetic (abdominal and thoracic),
and parasympathetic head and neck paragangliomas [34,
121–123]. The reported age at diagnosis is highly variable.
Missense and nonsense mutations have been found, without
any genotype-phenotype correlation [34, 121–123]. Recently,
SDHA gene mutations have also been implicated in the
development of gastrointestinal stromal tumors [124, 125].
2.3. Other Susceptibility Genes
2.3.1. TMEM127. TMEM127 is a tumor suppressor gene ini-
tially identified as a pheochromocytoma susceptibility gene
[37] and later also associated with the development of para-
gangliomas of head and neck and extra-adrenal abdominal
paragangliomas [126–130]. TMEM127 gene encodes a highly
conserved transmembrane protein, transmembrane protein
127, which is associated with several cellular organelles and
thought to limit mTORC1 activation thus controlling protein
synthesis and cell survival [37]. Mutations in this gene are
inherited in an autosomal dominant fashion and induce
tumor development by enhancing the kinase-dependent
signaling pathways, similarly to mutated RET and NF1
genes [37]. Patients may present either unilateral or bilateral
pheochromocytomas. The mean age at diagnosis is around
42 years and the risk of malignancy is very low (≈1%).
The prevalence of TMEM127 mutations in patients with
paraganglioma/pheochromocytoma varies between 0.9 and
2%. Different missense, frameshift, or nonsense TMEM127
mutations have been found across the three exons of the gene
[126, 129].
2.3.2. MAX. Comino-Me´ndez et al. identified mutations in
MAX gene as responsible for the development of bilateral
pheochromocytoma in eight index patients [38]. This asso-
ciation was further confirmed by another study comprising
1,694 patients with paraganglioma/pheochromocytoma [131].
The latter study documented MAX germline mutations in
23 nonrelated patients, all with adrenal tumors; among the
19 patients considered for phenotypic associations, 13 (68%)
presented with bilateral or multifocal pheochromocytoma
and 16% developed additional thoracoabdominal paragan-
gliomas [131]. Median age at diagnosis was 34 years and
37% of the patients had familial antecedents. Overall, MAX
germline mutations were found in 1.12% of patients without
other mutations [131]. Both studies presented patients with
metastatic disease, but further research is required to ascer-
tain the risk of malignancy associated with MAX mutations
[38, 131]. MAX tumors have an intermediate biochemical
phenotypewith a predominant normetanephrine release [131,
132].
MAX (myc-associated factor X) gene is a tumor suppres-
sor gene that encodes forMAXprotein, which is a component
of the MYC-MAX-MXD1 complex that regulates cell pro-
liferation, differentiation, and apoptosis [38, 133]. Mutations
in MAX gene have a paternal mode of transmission and are
responsible for the loss of the wild type allele with consequent
abrogation of protein expression. Consequently, inhibition
of MYC-dependent cell transformation by MAX protein is
disrupted, causing tumor development [38].
2.3.3. HIF2A and EGLN1. As stated before in the context of
VHL disease, HIF𝛼 proteins (HIF1𝛼, HIF2𝛼, and HIF3𝛼) are
transcription factors that respond to oxygen concentrations
in tissues. Under hypoxic conditions, stabilization of HIF𝛼
proteins occurs, allowing transcription of genes involved in
angiogenesis, glycolysis, erythropoiesis, apoptosis, prolifera-
tion and growth [134]. Mutations in VHL and SDHx genes
have been shown to induce pseudohypoxic states that induce
the development of paragangliomas/pheochromocytomas.
In 2012, Zhuang et al. described two somatic mutations
in the gene encoding of the hypoxia-inducible factor 2𝛼
(HIF2A) in two patients with polycythemia and multiple
paragangliomas (one of the patients also presented with
somatostatinomas). Functional assays show that both muta-
tions affected pVHL hydroxylation, impairing HIF2𝛼 degra-
dation leading to an intact/increased transcriptional activity
of genes downstream of HIF2𝛼, such as VEGFA and ery-
thropoietin [39].These findings were further corroborated by
other recent studies that confirmed somatic HIF2A gain-of-
function mutations as causative for the development of poly-
cythemia andmultiple paragangliomas/pheochromocytomas
and somatostatinomas in patients, corresponding to a novel
syndrome [135–142]. The occurrence of multiple tumors
presenting the same somatic mutations without familial
history suggests the occurrence of a de novo postzygotic
event early in the embryogenesis [39, 138]. Somaticmutations
in HIF2A have also been identified in sporadic pheochro-
mocytomas/paragangliomas in the absence of erythrocytosis
[137].
EGLN (egg-laying-defective nine) family of proteins (also
called PHD or HPH) are responsible for hydroxylation of
prolyl residues of HIF𝛼 under normoxic conditions, allow-
ing pVHL binding and proteosomal degradation of HIF𝛼
proteins [134]. The association between EGLN proteins and
paraganglioma development was first established by Ladroue
et al., by reporting a patient presenting with erythrocytosis
and recurrent abdominal paragangliomas who carried a
germline mutation in the EGLN1 gene (formerly known as
PHD2) [35]. Loss of heterozygosity involving the tumor wild
type EGLN1 allele suggests that EGLN1 may act as tumor-
suppressor gene. Functional studies indicate stabilization
of HIF2𝛼 in the presence of EGLN1 mutant protein [35].
Additional research is required to disclose the role of EGLN1
mutations in paragangliomas.
2.3.4. H-RAS. The RAS-ERK pathway has long been associ-
ated with the development of cancer [143]. Regarding para-
gangliomas/pheochromocytomas, it is currently accepted
that there are 2 distinct tumorigenesis clusters according
to their transcriptional profile: a pseudohypoxic cluster
(associated with mutations in VHL/SDHx/EGLN1 genes)
and a kinase receptor-signaling cluster (associated with
RET/NF1/TMEM127/MAX/KIF1Bmutations) [144]. Evidence
for a novel link between the latter cluster and paraganglioma
development has been provided by Crona et al., through
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the identification of somatic mutations in H-RAS gene in
four male patients presenting with pheochromocytoma (3
patients) and paraganglioma (1 patient) [40]. Very recently,
the same authors have described an additional H-RAS
somatic mutation in a patient with unilateral pheochromo-
cytoma [145].
2.3.5. KIF1B. Kinesin family member 1B (KIF1B) gene
expression results in two protein isoforms, KIF1B𝛼 and
KIF1B𝛽, which are motor proteins involved in the antero-
grade transport of mitochondria and synaptic vesicle precur-
sors, respectively [146, 147]. Schlisio et al. firstly associated
two KIF1B missense mutations as causative of pheochro-
mocytoma in two tumor samples [36]. It was also shown
that KIF1B𝛽 acts downstream from oxygen-dependent prolyl
hidroxylase EGLN3 (or PHD3) to induce apoptosis. These
loss of function mutations in KIF1B𝛽 could therefore protect
neuroblasts from apoptosis, leading to tumor development
[36]. This study was further extended to five relatives of a
patient harboring a germline KIF1B mutation. These indi-
viduals presented unilateral or bilateral pheochromocytoma
and other nonneural crest-derived malignancies, such as
ganglioneuroma, leiomyosarcoma, and lung adenocarcinoma
[148]. Transcriptional analysis of KIF1B𝛽 mutant pheochro-
mocytomas showed that these tumors are transcriptionally
related to RET and NF1-associated tumors.
3. Genetic Testing Strategy in
Paraganglioma/Pheochromocytoma
According to the general recommendation for genetic screen-
ing of the American Society of Clinical Oncology, all patients
with a risk of at least 10% of carrying a genetic muta-
tion should be offered genetic testing [149]. It is currently
accepted throughout the literature that about 35% of para-
ganglioma/pheochromocytoma cases are due to germline
mutations in one of the formerly described genes [41–43,
150, 151]. Therefore, it has been proposed by several authors
that genetic testing should be performed to all paragan-
glioma/pheochromocytoma patients [6, 41, 96, 151, 152].
In the clinical setting, hereditary paraganglioma/
pheochromocytoma syndromes should be considered in
all individuals with paragangliomas and/or pheochromo-
cytomas, particularly those with tumors that are multiple
and recurrent and have an early onset (age < 45 years).
Absence of a known family history is not enough to exclude
this hypothesis. However, there are subgroups of patients
with a very low risk as it is the case for those with apparently
sporadic paraganglioma/pheochromocytoma after age 50
[65, 151].
There are several meaningful motives in favor of offering
the genetic testing to paraganglioma patients. The inherited
syndromic forms caused by mutations in VHL, RET, and
NF1 genes are associated with other malignant tumors. Thus,
an early diagnosis of patients will allow an improved life-
long surveillance and forehand treatment with a consequent
improved prognosis [27–29]. On the other hand, patients
with germline mutations are more likely to have multiple
and recurrent paragangliomas/pheochromocytomas, which
requires a more close follow-up [6]. Molecular testing of
relatives will clarify their genetic status allowing excluding
thosewho did not inherit themutation fromunnecessary and
costly diagnostic procedures.
Advanced techniques like whole genome sequencing or
next-generation sequencing appear to be promising genetic
strategies for testing paraganglioma patients [153–155]. Nev-
ertheless, these techniques are still unavailable for many
genetic laboratories or remain far from being cost-effective.
To overcome a time consuming gene-after-gene analysis
and the difficulties associated with the overlapping clinical
features of several syndromic and sporadic forms, differ-
ent algorithms have been proposed based on a sequential
approach and taking into account the patient’s family history
and clinical presentation. Particular aspects such as the local-
ization of the primary tumor, the biochemical profile, and
age at diagnosis are considered of extreme relevance to orient
the genetic study. Herein, we propose an algorithm (Figure 1)
for genetic testing of paraganglioma/pheochromocytoma
patients that incorporates clinical data as well as information
derived fromprevious analytical reviews [48, 65, 150, 151, 156].
Patients presenting specific syndromic features or a pos-
itive familial history should be considered for the analy-
sis of the specific genes: VHL, RET, SDHB, SDHD, NF1,
or HIF2A [27–30, 33, 39]. For instance, the presence of
hemangioblastomas (suggestive of von Hippel-Lindau) or
medullary thyroid carcinoma along with pheochromocy-
toma (suggestive of MEN 2A) strongly implies mutations
in VHL or RET gene, respectively [27, 29]. The coexistence
of pheochromocytoma with interscapular pruritic lesions
strongly suggests a mutation in codon 634 of the RET gene
[157]. Expression of disease associated with a paternal trans-
mission mode, consistent with maternal imprinting, orients
genetic testing towards specific genes such as SDHD or,
more rarely, SDHAF2 [30, 106].Adrenal pheochromocytomas
(unilateral or bilateral) are more frequently associated with
VHL andRET.Thus, SDHB, SDHD,TMEM127, orMAX genes
should be considered only in a second step [37, 47, 80, 112,
131]. Extra-adrenal sympathetic paragangliomas (abdominal
or thoracic) are more frequently caused by SDHB, SDHD,
and VHL mutations [47, 77, 112]. Head and neck tumors are
more frequently caused by SDHD (especially in presence of
multiple tumors) and SDHB gene mutations and less often
by VHL and SDHC gene mutations [44, 50, 96]. If patients
are negative for mutations in these genes, SDHAF2 might
be considered for analysis [106]. Malignant tumors have
been strongly associated (>30%) with germline mutations
in SDHB, so initial analysis should address this gene [96].
If negative, then VHL, NF1, SDHD, or MAX genes can
be considered for investigation [48, 96, 131]. It should be
emphasized thatmutations in the above-described genesmay
result in atypical phenotypes therefore rendering oriented
genetic testing more complex.
A few and quick ways are likely to improve cost-
effectiveness of molecular genetic testing. For instance, in
VHL disease-associated pheochromocytoma, codon 167 of
VHL gene appears as a first target, since missense mutations
in this codon are strongly associated with pheochromocy-
toma development [60]. In addition, we should be aware
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Figure 1: Proposed algorithm for molecular genetic testing of paraganglioma/pheochromocytoma patients. The genes depicted in the boxes
are most likely to account for the clinical phenotype and should be analyzed in the proposed order. Mutations in TMEM127,MAX, HIF2A,
and SDHAF2 are extremely rare, so they should only be analyzed when patients are negative for the other gene mutations.
of founder mutations already reported for SDHx genes in
different countries such as the Netherlands, Poland, Italy,
Spain, and Portugal in order to develop effective screening
protocols [158–162].
Partial or large deletions may respond for false-negative
results, when using conventional PCR followed by automatic
sequencing techniques. Large deletions account for about
10% of the cases of SDHx-related paragangliomas [44]. Ide-
ally, laboratories would routinely use methods for searching
large genomic deletions such as quantitativemultiplex PCRof
short fluorescent fragments (QMPSF) or multiplex ligation-
dependent probe amplification (MLPA) in order to minimize
the risk of false-negative results.
Identification of a mutation allows tailoring treatment
and follow-up therefore contributing to a better prognosis.
The same holds true for the patients’ relatives. In the specific
cases of RET-associated pheochromocytoma, young relatives
carriers of RET mutations may undergo prophylactic thy-
roidectomy to prevent the development of medullary thyroid
carcinoma [67]. On the other hand, due to the higher risk
of malignancy in patients carrying SDHB gene mutations, a
closer biochemical and imaging follow-upmight be provided
in order to prevent the development of metastatic disease
[95].
4. Conclusions and Future Perspectives
A great deal of knowledge has been added to the genetics
of paragangliomas since the beginning of the millennium.
Until then, the genes responsible for inheritable forms of
paragangliomas were restricted to those underlying the syn-
dromic forms of the disease; RET gene in multiple endocrine
neoplasia type 2,VHL in vonHippel-Lindau disease; andNF1
in neurofibromatosis type 1. The discovery of the succinate
dehydrogenase genes associated with the development of
familial paraganglioma syndromes, in particular the SDHB
gene, frequently associated with malignant tumors, brought
new insights into the management and prognosis of paragan-
gliomas.
So far, at least 14 genes (RET, VHL, NF1, SDHA, SDHB,
SDHC, SDHD, SDHAF2, TMEM127, MAX, EGLN1, HIF2A,
H-RAS, and KIF1B) have been associated with the develop-
ment of paragangliomas. These genes have been divided into
two tumorigenesis clusters: a pseudohypoxic cluster (asso-
ciated with mutations in VHL/SDHx/EGLN1/HIF2A genes)
and a kinase receptor-signaling cluster (associated with
RET/NF1/TMEM127/MAX/KIF1B gene mutations). Func-
tional studies involving these genes and paraganglioma-
associated mutations as well as gene expression profiles of
tumor samples have greatly contributed to our understanding
of tumorigenic pathways of paragangliomas. Progresses in
genetic knowledge and the evidence for genotype-phenotype
correlations have largely influenced the care of patients with
positive impact.
In this review, we summarized the most relevant
aspects regarding the genetics and clinical aspects of the
syndromic and nonsyndromic forms of pheochromocy-
toma/paraganglioma aiming to provide an algorithm for
genetic testing. Recent comprehension of the molecular
pathways involved in the tumorigenesis of paragangliomas is
likely to be improved by further functional assays, possibly
hinting novel molecular-targeted therapy approaches.
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